about
sameAs
Disclosure of investigators' recruitment performance in multicenter clinical trials: a further step for research transparencyJournal editors impasse with outcome reporting bias.The International Committee of Medical Journal Editors trial data sharing requirement and participants' consent.Clinical trials transparency and access to anonymized individual participant data.Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain.ATA homozigosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study.Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae.Clinical trials committees: how long is the protocol review and approval process in Spain? A prospective study.[Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales].Informed consent for whole-genome sequencing studies in the clinical setting. Proposed recommendations on essential content and processNature and extent of changes in the patient's information sheets of international multicentre clinical trials as requested by Spanish Research Ethics Committees.Protections for clinical trials in low and middle income countries need strengthening not weakeningAttention deficit hyperactivity disorder: genetic association study in a cohort of Spanish childrenThe potential exploitation of research participants in high income countries who lack access to health careManaging incidental genomic findings in clinical trials: fulfillment of the principle of justice.Worldwide behavioral research on major global causes of mortality.Time to ensure that clinical trial appropriate results are actually published.Could phase 3 medicine trials be tagged as pragmatic? A case study: The Salford COPD trial.Public preferences on written informed consent for low-risk pragmatic clinical trials in Spain.Prevention of selective outcome reporting: let us start from the beginning.Who is willing to participate in low-risk pragmatic clinical trials without consent?Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reporting.Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects.Outcome reporting bias in clinical trials: why monitoring matters.Reactogenicity profile of a combined hepatitis A and B vaccine in clinical practice: a naturalistic study in adult travellers.Comparative trial to assess the reactogenicity of the diphtheria-tetanus-acellular pertussis (DTPa) vaccine plus Haemophilus influenzae type B (Hib) conjugate vaccine and that of the diphtheria-tetanus-whole cell pertussis (DTPw) vaccine plus Hib coImproving transparency of clinical trials.Patients' beliefs regarding informed consent for low-risk pragmatic trials.Why prudence is needed when interpreting articles reporting clinical trial results in mental healthWorldwide clinical interventional studies on leading causes of death: a descriptive analysis.Clinical observational research on Alzheimer's disease: what clinical trial registries can tell.Survey of emm-like gene sequences from pharyngeal isolates of group C and group G streptococci collected in Spain.Evaluating a newly developed pharmacogenetic array: screening in a Spanish population.Reply to Townsend et al.Number of citations 1 year after publication of trial results and their relation to medicines regulatory approval.Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers.CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment.Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue.Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers.
P50
Q28740869-B6966493-97BD-4472-82EF-E608B99AD358Q30488075-89AAF639-E858-495F-9B6D-65C50FEFAE54Q31139144-5A62BFD1-13A3-4049-8B7F-205273BDF1A4Q31149596-2ACC9FA7-49C2-4F1C-ABF5-0508840DC6F1Q33571285-0D15A4B4-73F1-4352-BF90-F69B4F69C49EQ33770121-7B35A2D5-0DE8-4796-9C23-16D77FF87182Q33928098-73A73E5F-A3EE-4D5E-B09B-0B291AC84399Q33946945-87A18620-1C88-4929-9A0E-8EFA333C44CBQ34411557-AA6637A7-E43F-4BD4-B680-85EAAAE7892DQ34522671-58C3BB2B-497A-4C12-B17C-15BA0F06E2C1Q34549035-DBED8E8D-341F-4EE0-876D-63D0A4588CA3Q35988150-A7E55F0F-3CFA-4E0C-A8A1-C5AB564770EEQ36396604-C3ACFE06-C3E9-4AD5-A95E-F0758F77E795Q36446301-22EEA70F-FB7E-4360-9420-67EF247395A1Q36806612-D6841E50-7479-4C3A-BBFB-69C2CC7007BCQ37477908-CC727B2E-3E6D-4878-ABCD-B186739C35D8Q37874047-EE3D0082-8A1F-49AE-BED6-10495C3B42FEQ38177648-5866A25B-83B3-436D-B40C-849B4019B67BQ38689738-D2EC57B8-70DE-4765-913F-323DC3EF3DCCQ38832151-B40DFD4C-F199-44C6-AD84-1C38EE945E6DQ38835242-29737DA8-D02C-4AD5-909E-A9247D8497C7Q40044320-B8BE8535-8691-48DB-8DB1-E3FF417EC4FCQ40049472-0BC4CD21-A888-43FA-B423-BE44D8E6136FQ40058190-D29A07EB-55CD-40EA-A667-085250F31D04Q40336283-FAD004DB-DD81-4CCA-8817-CAC79B376645Q40513506-D54DBC12-4CFB-43AE-8F57-2F0388C28950Q40589747-85FF9ED3-88AB-4B07-9CDC-20EE882E3FD9Q41570206-1DAA05ED-5941-4230-A248-E3866C90A5E7Q41711995-A3B0E540-0672-4D81-AC24-9707BB009220Q42370783-24C15045-E5FF-4AC2-BB58-A468B089B496Q42600024-5D644423-7288-4794-99B6-BE2B818C14BAQ42678398-8A9D993E-F61D-4811-BACE-9932D20437E6Q42721987-CE86BA57-2DDA-46DF-A622-2424126BAA4CQ42788951-799D4A36-B145-4C29-BE1F-33F979443427Q42790155-C1608BF3-C2CC-4F2A-898B-B3051503F19AQ42944236-C0EEB8D4-920B-42B5-9741-BE376F3AD36FQ44876354-FACC6276-3F2A-42EA-AB33-7D232BE8C98EQ45292606-9FF93CA7-5576-4485-9C87-A4113E07D187Q45422018-17DFC36B-392A-4CE9-B282-8D87D1A4A3FAQ46443969-AA8C82CC-6892-4DDA-8077-AF0785548019
P50
description
Spaans bio-ingenieur
@nl
ingeniero agrónomo español
@es
name
Rafael Dal-Ré Tenreiro
@de
Rafael Dal-Ré Tenreiro
@en
Rafael Dal-Ré Tenreiro
@es
Rafael Dal-Ré Tenreiro
@fr
Rafael Dal-Ré Tenreiro
@gl
Rafael Dal-Ré Tenreiro
@it
Rafael Dal-Ré Tenreiro
@nl
Rafael Dal-Ré Tenreiro
@pt
Rafael Dal-Ré Tenreiro
@sl
Rafael Dal-Ré Tenreiro
@sv
type
label
Rafael Dal-Ré Tenreiro
@de
Rafael Dal-Ré Tenreiro
@en
Rafael Dal-Ré Tenreiro
@es
Rafael Dal-Ré Tenreiro
@fr
Rafael Dal-Ré Tenreiro
@gl
Rafael Dal-Ré Tenreiro
@it
Rafael Dal-Ré Tenreiro
@nl
Rafael Dal-Ré Tenreiro
@pt
Rafael Dal-Ré Tenreiro
@sl
Rafael Dal-Ré Tenreiro
@sv
prefLabel
Rafael Dal-Ré Tenreiro
@de
Rafael Dal-Ré Tenreiro
@en
Rafael Dal-Ré Tenreiro
@es
Rafael Dal-Ré Tenreiro
@fr
Rafael Dal-Ré Tenreiro
@gl
Rafael Dal-Ré Tenreiro
@it
Rafael Dal-Ré Tenreiro
@nl
Rafael Dal-Ré Tenreiro
@pt
Rafael Dal-Ré Tenreiro
@sl
Rafael Dal-Ré Tenreiro
@sv
P1006
P214
P244
P950
P1006
P1607
P21
P214
P244
no2004085683
P27
P31
P496
0000-0002-0980-2486